Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Bernard Charbonnel,
Dr. John McMurray,
Presenter | see Discussant report
John McMurray, FESC (United Kingdom)Presentation webcast
List of Authors: J McMurray, M Komajda, H Beck-Nielsen, R Gomis, M Hanefeld, S Pocock, P Curtis, N Jones & P Home on behalf of the RECORD Committees and Investigators
Concern had been raised that treatment with rosiglitazone might increase the risk of myocardial infarction in patients with diabetes on the basis of a meta-analysis of small, short-term, trials that had methodological limitations (Nissen and Wolski N Engl J Med 2007; 356: 2457-71) . The present analyses describe the occurrence of prospectively identified coronary events occurring during a large-scale, long-term (average follow-up 5.5 years), randomized trial comparing treatment with rosiglitazone added to background metformin or sulfonylurea monotherapy (n=2220) with combination metformin plus sulfonylurea treatment (n=2227) in patients with type II diabetes mellitus – the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD) study. All events were adjudicated by an endpoint committee blinded to treatment allocation using pre-specified definitions. The composite outcome of fatal and non-fatal myocardial infarction (a pre-defined secondary endpoint) was reported in the primary paper (Home et al Lancet 2009; 373; 2125-35). The present report describes i) subsequent acute coronary events and mortality in these patients ii) a range of post hoc composite coronary outcomes, analysed as time to first event and iii) total coronary events, taking account of recurrent events (i.e. that patients can experience more than one event). The additional coronary composites analysed included a) Any acute coronary syndrome (fatal MI, sudden death, hospitalization for cardiac arrest, hospitalization for acute MI or hospitalization for unstable angina) b) Any acute coronary syndrome (ACS) or other angina (above plus patients with an “other” cardiovascular hospitalization attributed to angina pectoris) and c) Any ACS, other angina or coronary revascularization (above plus either percutaneous coronary intervention or coronary artery bypass surgery). The attached slides show these outcomes. Among the 60 survivors of a first MI in the rosiglitazone group, there were 7 recurrent MIs and 3 cases of unstable angina pectoris. There were 11 deaths (of which 7 were cardiovascular). Among the 52 survivors of a first MI in the control group (metformin plus a sulfonylurea), there were 11 recurrent MIs and 2 cases of angina pectoris. There were 12 deaths (of which 10 were cardiovascular). The expanded coronary composites showed similar event rates in both treatment groups. The total number of coronary events were similar in the two groups – for the broadest composite, 127 patients in the rosiglitazone group experienced 221 events compared to 128 patients (230 events) in the control group. In summary, there was no statistically significant increase in coronary events in patients treated with rosiglitazone in the RECORD trial.
Discussant | see Presenter abstract
Bernard Charbonnel, FESC (France)
Effect of rosiglitazone on coronary events in the RECORD study
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.